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Prescription Changes
As a reminder, changes to the Permitted Prescription 
Changes and Additions policy allow pharmacists to change 
days supply dispensed (eg, 30-day supply with 11 refills 
versus 90-day supply with three refills or vice versa) without 
consulting the prescriber. However, this is not permissible for 
drugs that must be reported to the prescription monitoring 
program, including gabapentin. Pharmacists are advised to 
exercise extreme caution with drug classes where a change 
in days supply may put a patient at risk. Narrow therapeutic 
index drugs (eg, lithium, warfarin) and behavioral health 
drugs (eg, antipsychotics, antidepressants) are two classes of 
drugs where changing the days supply may not be appropriate. 
Before changing the days supply, it is strongly recommended 
to consult prescribers upon initiation of new therapy and 
changes for any drugs that may be of concern.
Voluntary Assessments for Institutional 
Sterile Compounders
The proposed regulation Draft 247 Code of Massachusetts 
Regulations 6.00: Licensure of Pharmacies will require the 
Massachusetts Board of Registration in Pharmacy to license 
and inspect institutional sterile compounding pharmacies. 
In preparation, “voluntary assessments” are available for 
those future licensees (eg, clinic and hospital pharmacies) to 
have the opportunity for a Board inspector to assess sterile 
compounding areas for compliance with current United 
States Pharmacopeia (USP) standards, as well as make 
recommendations in view of future Massachusetts regulations 
and USP revisions. This is an opportunity for education, 
informal feedback, development of cross collaboration, and 
help with resource planning. 
The assessments would evaluate the following areas: 
facility, standard operating procedures, certifications, envi-
ronmental monitoring, employee training, cleaning, personnel 
garbing, compliance, and verification practices. To date, 15 
assessments have been performed with many observational 
findings supporting the need for some upgrades or renovations 
in order to become compliant with USP General Chapters 
<797> and <800>. 
The voluntary assessment would take place at a mutually 
agreeable date and time, and at the conclusion of the 
assessment, Board investigators will provide the completed 
assessment document and discuss observations in detail. 
If interested in participating in a voluntary assessment, 
directors of pharmacy or other authorized representatives 
may contact Nathan Van Allen via email at nathan.vanallen@
massmail.state.ma.us. The current coronavirus disease 2019 
(COVID-19) situation may affect availability. 
Getting to Know the Board Staff –  
Rick Harris
As a member of the Board staff, Rick serves as the program 
analyst. He came to the Board after 25 years of working 
with children and families in a variety of settings in both 
Massachusetts and Connecticut. Along the way, Rick has kept 
busy as a published author, composer, singer, and had a brief 
stint in the Actors’ Equity Association. He has also served as 
an emergency medical technician and an instructor/trainer in 
water safety, first aid, and CPR.
When Rick first joined the Bureau of Health Professions 
Licensure, he worked in the office of public protection and 
then joined the Board in 2014. He wears a variety of hats, 
but his primary focus is licensing. Rick helps pave the way 
for individuals and facilities navigating the licensing process. 
This means providing organizational systems, assisting ap-
plicants, troubleshooting problems, and answering various 
questions about the licensing process. 
Rick works closely with applicants who have had previous 
legal difficulties or who have received discipline on a profes-
sional license here in Massachusetts or in other jurisdictions. 
These “Good Moral Character” applicants often need support 
and guidance as they prepare to appear before the Board. 
Rick says, “It is one of my favorite parts of my job. I get to 
work with people who have made some mistakes in the past 
but are trying hard to move forward with their careers. I find 
that very rewarding.” 
239 Causeway Street, 5th Floor • Boston, MA  02114 • www.mass.gov/dph/boards/pharmacy
May 2020
Published to promote compliance of pharmacy and drug law
News
Massachusetts Board
of Registration in Pharmacy
counterfeit pills made to look like prescription opioids 
and powder. Fentanyl remains the “primary driver” of the 
current opioid crisis, according to the report.  
“Illicit drugs, and the criminal organizations that 
traffic them, continue to represent significant threats to 
public health, law enforcement, and national security in 
the United States,” a DEA press release states. “As the 
National Drug Threat Assessment describes, the opioid 
threat continues at epidemic levels, affecting large 
portions of the United States.”
Drug-Resistant Infections Are 
Increasing
A new report on antibiotic infections released by 
the Centers for Disease Control and Prevention (CDC) 
estimates more than 2.8 million antibiotic-resistant 
infections occur each year, and more than 35,000 
Americans are dying annually as a result. While the report 
notes that prevention and infection control efforts in the 
US are working to reduce the number of infections and 
deaths caused by antibiotic-resistant germs, the number of 
people facing antibiotic resistance is still too high. “More 
action is needed to fully protect people,” the report states.
The report lists 18 antibiotic-resistant bacteria and 
fungi and places them into three categories (urgent, seri-
ous, and concerning) based on clinical impact, economic 
impact, incidence, 10-year projection of incidence, trans-
missibility, availability of effective antibiotics, and barri-
ers to prevention. It also highlights estimated infections 
and deaths since the last CDC report in 2013, aggressive 
actions taken, and gaps that are slowing progress. 
The full report is available on the CDC website.
NASEM Report Recommends 
Framework for Opioid Prescribing 
Guidelines for Acute Pain
Contracted by Food and Drug Administration (FDA), 
a December 2019 report by the National Academies of 
Sciences, Engineering, and Medicine (NASEM) seeks 
to develop evidence-based clinical practice guidelines 
for prescribing opioids for acute pain. The report, 
Framing Opioid Prescribing Guidelines for Acute Pain: 
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President Trump Signs Legislation 
Extending Schedule I Status for 
Fentanyl Analogues
A law to extend the Schedule I status of fentanyl 
analogues for another 15 months was signed into law by 
President Donald J. Trump on February 6, 2020. Synthetic 
fentanyl analogues, often illegally manufactured, are 
widely believed to be fueling the “third wave” of the 
opioid crisis, as detailed in the October 2019 issue of 
Innovations®(pages 8-11), which can be accessed through 
the Publications section of the National Association of 
Boards of Pharmacy®’s website. 
In February 2018, Drug Enforcement Administration 
(DEA) issued a temporary order to establish fentanyl-
related substances as Schedule I. The Temporary Reau-
thorization and Study of the Emergency Scheduling of 
Fentanyl Analogues Act extends the DEA order, which 
was set to expire on February 6, 2020. The bill requires 
the Government Accountability Office to produce a report 
within 12 months on the public health and safety effects 
of controlling fentanyl-related substances, according to 
Homeland Preparedness News. 
Drug Overdose Deaths Related to 
Prescription Opioids Declined by 13% 
in 2018
Fatalities related to the use of prescription opioids 
declined by 13% in the United States during 2018, 
according to the 2019 National Drug Threat Assessment 
released by DEA. Despite this encouraging news, the 
report makes it clear that the opioid crisis continues at 
epidemic levels. Specifically, controlled prescription 
drugs remain a major factor in the record number of 
overdose deaths since 2017. Benzodiazepines and 
antidepressants were involved in an increasing number 
of overdose deaths. 
Fentanyl and similar synthetic opioids also remain 
a major point of concern. Fentanyl maintained high 
availability through most of the US in 2018. Illegally 
manufactured versions of the powerful opioid continue 
to be smuggled into the US, primarily in the form of 
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Developing the Evidence, also develops a framework to 
evaluate existing guidelines, and recommends indications 
for which new evidence-based guidelines should be 
recommended. 
As part of its work, NASEM examined existing opioid 
analgesic prescribing guidelines, identified where there 
were gaps in evidence, and outlined the type of research 
that will be needed to fill these gaps. NASEM also held 
a series of meetings and public workshops to engage 
a broad range of stakeholders who contributed expert 
knowledge on existing guidelines, and provided emerging 
evidence or identified specific policy issues related to 
the development and availability of opioid analgesic 
prescribing guidelines based on their specialties.
“We recognize the critical role that health care providers 
play in addressing the opioid crisis – both in reducing 
the rate of new addiction by decreasing unnecessary or 
inappropriate exposure to opioid analgesics, while still 
providing appropriate pain treatment to patients who 
have medical needs for these medicines,” said Janet 
Woodcock, MD, director of FDA’s Center for Drug 
Evaluation and Research in a statement. “However, 
there are still too many prescriptions written for opioid 
analgesics for durations of use longer than are appropriate 
for the medical need being addressed. The FDA’s efforts 
to address the opioid crisis must focus on encouraging 
‘right size’ prescribing of opioid pain medication as well 
as reducing the number of people unnecessarily exposed 
to opioids, while ensuring appropriate access to address 
the medical needs of patients experiencing pain severe 
enough to warrant treatment with opioids.”
FDA will next consider the recommendations included 
in the report as part of the agency’s efforts to implement 
the SUPPORT Act provision requiring the development of 
evidence-based opioid analgesic prescribing guidelines.
The report can be downloaded for free on the NASEM 
website. 
New Research Shows Pharmacists 
Positively Impact Hospital Care 
Transitions
Patients who received focused attention from 
pharmacists during hospital stays expressed higher 
satisfaction, according to research presented at the 
American Society of Health-System Pharmacists 
Midyear Clinical Meeting and Exhibition. The study 
centered on the effect of pharmacists educating patients 
about medications as they transitioned out of hospital 
care. During the study, pharmacists reconciled patients’ 
medications before discharge, talked with patients about 
the medications they were taking, and contacted them by 
phone after discharge to discuss their care.
Of the 1,728 patients included in the study, 414 
received the full transition-of-care education protocol, 
including a follow-up pharmacist phone call. Those 
patients showed a 14.7% increase in the overall average 
mean score, as measured by the Hospital Consumer 
Assessment of Healthcare Providers and Systems survey, 
which assesses patients’ perceptions of their care after 
discharge. A post hoc analysis also showed that 30-day 
readmission rates dropped from 17.3% to 12.4% when 
a post-discharge phone call was made to patients as a 
part of the study.
“Pharmacists play a multitude of vital roles for 
patients during a hospital stay, including comprehensive 
medication management and ensuring medication safety. 
Now, they can feel increasingly confident about their 
role in helping patients when transitioning from different 
levels of care. Our findings add to growing literature 
demonstrating that pharmacist involvement in hospital 
discharge improves outcomes and safety,” said Katherine 
L. March, PharmD, BCPS, clinical pharmacy specialist
at Methodist University Hospital in Memphis, TN, in a
press release.
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Security Cameras
There are many measures that pharmacies and pharmacists 
can employ to guard against controlled substance (CS) loss 
and diversion. These range from policies and physical security 
methods, to more sophisticated video surveillance. In addition 
to investigations of drug losses, security cameras can also 
minimize opportunities for theft or diversion and should be 
an integral part of a comprehensive security plan. The main 
goals of any pharmacy security camera system are to protect 
employees and customers as well as safeguard the security 
of the drugs. 
One consideration is for pharmacies to perform a risk 
assessment of the vulnerabilities of the pharmacy to 
determine how to implement and maximize the use of video 
surveillance. Strategically placed high-resolution security 
cameras can cover all areas where employees interact with 
CS and deter opportunities for undetected employee theft. 
Cameras should capture entrances and exits, as well as any 
areas CS are received, stored, dispensed, counted, held, or 
returned to stock, and should also have a clear view of the 
point of sale locations. 
A quality security camera system can be a valuable tool to 
help investigate a loss or otherwise determine what happened 
to a particular prescription during the filling and pickup 
processes. A review of security footage may conclusively 
determine that a full bottle of medication was inadvertently 
discarded in the trash or identify the culprit of a theft. Without 
security footage, these issues could not be resolved.
Another consideration is video retention. During the risk 
assessment, the pharmacy should determine a realistic time 
frame between audits and manual inventory counts to decide 
how long to keep footage. Having security cameras and 
a minimum retention period for the videos will help with 
investigations as well as deter theft.
Identification Requirements
Patients or their agents do not need an ID to pick up 
prescriptions for federally scheduled CS in certain circum-
stances. However, an individual must print his or her name 
and address on the reverse side of the prescription and sign 
it. In the case of an electronic prescription, he or she must 
provide an electronic signature. Review the Data Submission 
Dispenser Guide for details.
Did You Know?
 ♦ Veterinarians do not have National Provider Identifier 
numbers and are not required to provide their Drug 
Enforcement Administration (DEA) numbers for 
Schedule VI prescriptions. Contact your help desk/IT 
department if you need assistance adding veterinarians 
to your computer system. 
 ♦ COVID-19 updates and resources can be found on the 
Board’s website.
 ♦ Be aware of unusual calls or emails from the Federal 
Bureau of Investigation, DEA, or the Board asking for 
identifying information or money. There have been 
reports of calls and emails that appear to have originated 
from official agencies but are really from spoofed phone 
numbers or emails. The Board will never call to ask you 
for money. If you have concerns, verify the requestor’s 
identity through other means before acting on suspicious 
communications.
 ♦ Review your own knowledge and help your interns study 
for the Multistate Pharmacy Jurisprudence Examination® 
with these references. 
 ♦ You can always ask pharmacy practice questions at 
Pharmacy.admin@massmail.state.ma.us.
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